ScinoPharm to Provide Contract Manufacturing Service for Newly Approved Antidepressant Drug in the United States

TAINAN, Taiwan, February 8, 2011 - ScinoPharm, a leading active pharmaceutical ingredient (API) and contract
research and manufacturing (CRAM) service provider to the global
pharmaceutical and biotechnology industry, will provide commercial
manufacturing service of vilazodone hydrochloride active pharmaceutical
ingredient (API) for Clinical Data, Inc.'s Viibryd(TM), a new drug entity
recently approved by the United States Food and Drug Administration.

Viibryd is a novel drug for the treatment of adults with major depressive
disorder (MDD). The drug's dual mechanism of action and side effect profile
differentiates itself from other antidepressants. Use of Viibryd did not
cause significant weight gain or interference with sexual function as seen
with some rival drugs.

"ScinoPharm is proud of the fruitful partnership with Clinical Data by
being its sole API supplier of vilazodone hydrochloride during Viibryd's
launch. Beginning from process research through timely development and
optimization of long and complicated synthetic processes, we have established
a win-win partnership," said Dr. Jo Shen, President and CEO of ScinoPharm.

In relationship similar to the one with Clinical Data, ScinoPharm
partners with other leading pharmaceutical companies for custom contract
services from clinical materials to commercial. So far the company has
handled more than 60 NCE projects, with 4 currently in phase III and 3 having
already been approved for launch.

ScinoPharm is set to expand its CRAM services through its new GMP plant
in Changshu, China, which is expected to be operational in Q3 2011. The
Changshu plant will expand the company's overall R&D and production
capabilities to capture the business opportunities in the rapidly expanding
Asian pharmaceutical market.

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing
service provider to the global pharmaceutical industry. With research and
manufacturing facilities in both Taiwan and China, ScinoPharm offers a wide
portfolio of services ranging from custom synthesis for early phase
pharmaceutical activities to brand companies as well as APIs for the generic
industry. For more information, please visit the Company's website at
www.scinopharm.com.

About Clinical Data, Inc.

Clinical Data's mission is to develop first-in-class and best-in-category
therapeutics. The Company's lead product, Viibryd, was approved for marketing
by the FDA for the treatment of major depressive disorder in adults. The
Company is also advancing its late-stage drug candidate, Stedivaze, a
pharmacologic stress agent in Phase III development for use during myocardial
perfusion imaging. Clinical Data has promising drug candidates entering the
clinic in major therapeutic areas including asthma, ophthalmology and
diabetes. To learn more, please visit the Company's website at
www.clda.com.

    Media Contact:
    ScinoPharm Taiwan, Ltd.
    Sabrian Wu
    TEL: +886-6-508-2869
    Mobile Phone: +886-920-056-385
    Email: sabrina.wu@scinopharm.com.tw

ScinoPharm Taiwan, Ltd., Sabrian Wu, +886-6-508-2869, Mobile, +886-920-056-385, sabrina.wu at scinopharm.com.tw